MI-773 (SAR405838) (C007B-231391)

InformationMI-773 (SAR405838) MI-773 (SAR405838) is an orally available MDM2 antagonist with K i of 0.88 nM. Phase 1.Targetsp53 ; MDM2 (Cell-free assay) ; 0.88 nM(Ki)In vitroMI-773 binds to MDM2 with Ki of 0.88 nM. MI-773 potently inhibits cell growth in cancer cell lines, including SJSA-1 (IC50, 0.092 μM), RS4;11 (IC50, 0.089 μM), LNCaP (IC50, 0.27 μM), and HCT-116 (IC50, 0.20 μM) cells, and displays high selectivity over cancer cell lines with mutated or deleted p53, including SAOS-2 (IC50, >10 μM), PC-3 (IC50, >10 μM), SW620 (IC50, >10 μM), and HCT-116 (p53-/-) (IC50, >20 μM) cells.In vivoIn the SJSA-1 osteosarcoma, acute lymphoblastic leukemia RS4;11, LNCaP prostate cancer, and HCT-116 colon cancer xenograft model, MI-773 (p.o.) effectively inhibits tumor growth in a dose-dependent manner (10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg,).Cell Research(from reference)Cell lines：SJSA-1, RS4;11, LNCaP, SAOS-2, PC-3, SW620, HCT-116, and HCT-116 (p53-/-) cells Concentrations：100 μM Incubation Time：~48 h.

Specifications and Purity: 10mM in DMSO

Molecular Formula: C29H34Cl2FN3O3

Molecular Weight: 562.5

PubChem CID: 53476877

Isomeric SMILES: CC(C)(C)C[C@H]1[C@@]2([C@H]([C@@H](N1)C(=O)NC3CCC(CC3)O)C4=C(C(=CC=C4)Cl)F)C5=C(C=C(C=C5)Cl)NC2=O